{
    "hands_on_practices": [
        {
            "introduction": "A highly accurate screening test is not useful on its own; its practical value is deeply connected to the prevalence of the disease in the population being tested. This exercise uses Bayes' theorem to demonstrate the critical relationship between disease prevalence and Positive Predictive Value (PPV). By calculating the minimum prevalence required for a positive result to be more likely true than false, you will gain a quantitative appreciation for why a sufficiently high prevalence is a core characteristic of a screenable disease .",
            "id": "4577378",
            "problem": "A health department is evaluating whether a condition is suitable for general population screening using a single binary test. The test has sensitivity $0.90$ and specificity $0.95$. Using Bayes’ theorem and the core definitions of sensitivity, specificity, prevalence, and positive predictive value (PPV), derive from first principles the minimal population prevalence $p$ such that the positive predictive value (PPV) is at least $0.5$. Then, based on this threshold, briefly discuss the feasibility of achieving such PPV in general population screening programs for chronic diseases, emphasizing how this relates to a key characteristic of a screenable disease (sufficiently high prevalence in the target population).\n\nExpress the final prevalence threshold as an exact fraction or an exact decimal. Do not round and do not use a percent sign. Your final answer must be a single number.",
            "solution": "The problem is assessed to be valid as it is scientifically grounded in the principles of epidemiology and probability theory, is well-posed with a clear objective and sufficient data, and is expressed objectively.\n\nWe are tasked with deriving the minimal population prevalence $p$ for a disease such that a screening test with given characteristics achieves a positive predictive value (PPV) of at least $0.5$.\n\nFirst, let us define the relevant terms from first principles.\nLet $D$ be the event that an individual has the disease.\nLet $D^c$ be the event that an individual does not have the disease.\nLet $T^+$ be the event of a positive test result.\nLet $T^-$ be the event of a negative test result.\n\nThe problem provides the following quantities:\n-   **Prevalence ($p$)**: This is the prior probability of an individual having the disease, $P(D) = p$. Consequently, the probability of not having the disease is $P(D^c) = 1 - p$.\n-   **Sensitivity ($\\text{sens}$)**: The probability that the test is positive, given that the individual has the disease. It is the true positive rate.\n    $$ \\text{sens} = P(T^+ | D) = 0.90 $$\n-   **Specificity ($\\text{spec}$)**: The probability that the test is negative, given that the individual does not have the disease. It is the true negative rate.\n    $$ \\text{spec} = P(T^- | D^c) = 0.95 $$\nFrom specificity, we can derive the false positive rate, which is the probability of a positive test given the individual does not have the disease:\n    $$ P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - \\text{spec} = 1 - 0.95 = 0.05 $$\n\nThe quantity we need to evaluate is the **Positive Predictive Value (PPV)**, which is the probability that an individual actually has the disease, given that they have tested positive. Using the definition of conditional probability, we have:\n$$ \\text{PPV} = P(D | T^+) $$\n\nWe apply Bayes' theorem to express PPV in terms of prevalence, sensitivity, and specificity:\n$$ \\text{PPV} = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)} $$\nThe denominator, $P(T^+)$, is the total probability of a positive test result in the population. We can expand it using the law of total probability:\n$$ P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c) $$\nSubstituting the terms we have defined:\n$$ P(T^+) = (\\text{sens})(p) + (1 - \\text{spec})(1 - p) $$\nNow, we substitute this back into the expression for PPV:\n$$ \\text{PPV} = \\frac{(\\text{sens})(p)}{(\\text{sens})(p) + (1 - \\text{spec})(1 - p)} $$\nThe problem requires that the PPV be at least $0.5$:\n$$ \\frac{(\\text{sens})(p)}{(\\text{sens})(p) + (1 - \\text{spec})(1 - p)} \\ge 0.5 $$\nWe can now substitute the given numerical values for sensitivity and specificity:\n$$ \\frac{0.90 p}{0.90 p + (0.05)(1 - p)} \\ge 0.5 $$\nTo solve for $p$, we can multiply both sides by the denominator. Since $p$ represents a prevalence, $0 \\le p \\le 1$, and the sensitivity and specificity are positive, the denominator is always positive. Thus, the direction of the inequality is preserved.\n$$ 0.90 p \\ge 0.5 [0.90 p + 0.05 (1 - p)] $$\n$$ 0.90 p \\ge 0.45 p + 0.025 (1 - p) $$\n$$ 0.90 p \\ge 0.45 p + 0.025 - 0.025 p $$\nCombine the terms involving $p$ on the right-hand side:\n$$ 0.90 p \\ge 0.425 p + 0.025 $$\nSubtract $0.425 p$ from both sides to isolate the terms with $p$:\n$$ (0.90 - 0.425) p \\ge 0.025 $$\n$$ 0.475 p \\ge 0.025 $$\nFinally, we solve for $p$:\n$$ p \\ge \\frac{0.025}{0.475} $$\nTo express this as an exact fraction, we can multiply the numerator and the denominator by $1000$:\n$$ p \\ge \\frac{25}{475} $$\nDividing the numerator and the denominator by their greatest common divisor, which is $25$:\n$$ p \\ge \\frac{25 \\div 25}{475 \\div 25} = \\frac{1}{19} $$\nThe minimal population prevalence $p$ required for the PPV to be at least $0.5$ is therefore $\\frac{1}{19}$.\n\nFor the discussion part of the problem:\nThe calculated prevalence threshold of $p = \\frac{1}{19}$ (approximately $0.0526$ or $5.26\\%$) is the minimum prevalence required in the screened population for a positive test result to be more likely true than false. This result directly relates to a key characteristic of a screenable disease: the disease must have a sufficiently high prevalence in the target population.\n\nThis threshold highlights a fundamental challenge for general population screening programs for many chronic diseases. The prevalence of numerous conditions, such as many types of cancer or inborn errors of metabolism, is often far below $5\\%$ in the general, unselected population. When a test, even one with high sensitivity and specificity like the one in this problem, is applied to a low-prevalence population, the number of false positives can vastly outnumber the true positives, resulting in a low PPV. A low PPV implies that a majority of individuals with positive results are actually disease-free, leading to significant harms including patient anxiety, costs and risks of unnecessary confirmatory diagnostic procedures, and the potential for overdiagnosis and overtreatment.\n\nTherefore, achieving a medically acceptable PPV is often not feasible for rare diseases through general population screening. This is why effective screening programs are frequently aimed at high-risk subpopulations (e.g., based on age, family history, or genetic markers) where the disease prevalence is considerably higher than in the general population, thereby increasing the PPV to a more acceptable level and improving the benefit-to-harm ratio of the screening intervention.",
            "answer": "$$\\boxed{\\frac{1}{19}}$$"
        },
        {
            "introduction": "When a new screening program reports that patients are living longer after diagnosis, it is essential to distinguish real therapeutic benefit from mere statistical artifacts. This practice illuminates a major pitfall in program evaluation known as \"lead-time bias,\" where screening appears to prolong survival simply by diagnosing the disease earlier without changing its natural course. This exercise will help you critically assess whether an observed increase in survival is a true benefit or an illusion created by the lead time .",
            "id": "4577406",
            "problem": "In a population with a disease that has a detectable preclinical phase, assume the following timeline of events for an individual case: biological onset occurs at time $0$, clinical diagnosis (in the absence of screening) occurs at time $S > 0$ after onset, and death occurs at time $T > 0$ after onset. A screening program is implemented that advances the time of diagnosis by a lead time $L \\in (0, S)$, without changing the time of death (that is, there is no treatment effect on mortality; only earlier diagnosis). The observed post-diagnosis survival is defined as the interval from the time of diagnosis to the time of death.\n\nUsing only core definitions of survival time and lead time, and without assuming any special parametric distributions, derive the observed post-diagnosis survival under screening as a function of $L$, $S$, and $T$, and compare it to the observed post-diagnosis survival without screening. Then, from first principles, derive the multiplicative change in mean observed post-diagnosis survival that an Uncontrolled Before-After (UBA) comparison would report when screening is introduced, given that the true time of death is unaffected by screening.\n\nFinally, consider a scientifically plausible scenario in which the mean true survival from biological onset to death is $\\mathbb{E}[T] = 10$ years, the mean time from onset to clinical diagnosis in the absence of screening is $\\mathbb{E}[S] = 4$ years, and the screening program advances diagnosis by a constant lead time of $L = 1.5$ years. Under the assumptions above, compute the UBA-reported multiplicative change in mean observed post-diagnosis survival when screening is introduced. Round your final answer to four significant figures and express it as a dimensionless decimal factor.",
            "solution": "The problem statement is first validated against the required criteria.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Timeline of events for a disease case:\n    - Biological onset at time $0$.\n    - Clinical diagnosis without screening occurs at time $S > 0$.\n    - Death occurs at time $T > 0$.\n- A screening program is implemented with the following effects:\n    - It advances the time of diagnosis by a lead time $L \\in (0, S)$.\n    - It does not change the time of death $T$.\n- Definition:\n    - Observed post-diagnosis survival is the time interval from diagnosis to death.\n- Tasks:\n    1. Derive the observed post-diagnosis survival under screening as a function of $L$, $S$, and $T$.\n    2. Compare this to the observed post-diagnosis survival without screening.\n    3. Derive the multiplicative change in mean observed post-diagnosis survival that an Uncontrolled Before-After (UBA) comparison would report.\n    4. Compute this multiplicative change for the specific case where:\n        - Mean true survival from onset to death, $\\mathbb{E}[T] = 10$ years.\n        - Mean time from onset to clinical diagnosis (no screening), $\\mathbb{E}[S] = 4$ years.\n        - Constant lead time, $L = 1.5$ years.\n- Final Answer Requirement:\n    - Round the numerical result to four significant figures.\n    - Express it as a dimensionless decimal factor.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded (Critical):** The problem is scientifically grounded. It presents a simplified but standard and fundamental model used in epidemiology to explain and quantify \"lead-time bias,\" a critical concept in the evaluation of screening programs. The model's assumptions (fixed timeline, earlier diagnosis without affecting mortality) are deliberate simplifications to isolate and illustrate this specific bias.\n- **Well-Posed:** The problem is well-posed. All variables ($S$, $T$, $L$) and constants ($\\mathbb{E}[T]$, $\\mathbb{E}[S]$) are clearly defined. The objectives are stated unambiguously, and the provided information is sufficient to derive a unique solution.\n- **Objective (Critical):** The problem is stated in objective, precise, and formal language, using standard terminology from epidemiology and statistics. It is free from subjective or opinion-based claims.\n\n**Step 3: Verdict and Action**\nThe problem is valid. It is a standard, well-posed problem in epidemiology that requires a rigorous derivation from first principles. The solution process will proceed.\n\n### Solution Derivation\n\nLet us define the relevant time intervals based on the problem statement. The reference point is the time of biological onset, denoted as $t=0$.\n\nFirst, we consider the case without a screening program.\nThe time of diagnosis is given as $S$.\nThe time of death is given as $T$.\nThe observed post-diagnosis survival, which we denote as $U_{no\\_screen}$, is the duration from the time of diagnosis to the time of death.\nTherefore,\n$$U_{no\\_screen} = T - S$$\nFor this survival time to be physically meaningful (i.e., positive), it is implicit that $T > S$.\n\nNext, we consider the case with the screening program.\nThe screening program advances the time of diagnosis by a lead time $L$. The original time of diagnosis was $S$, so the new, earlier time of diagnosis is $S - L$.\nThe problem states that screening does not change the time of death, so it remains $T$.\nThe observed post-diagnosis survival under screening, which we denote as $U_{screen}$, is the duration from the new time of diagnosis to the time of death.\nTherefore,\n$$U_{screen} = T - (S - L) = T - S + L$$\n\nComparing the two observed survival times, we can express $U_{screen}$ in terms of $U_{no\\_screen}$:\n$$U_{screen} = (T - S) + L = U_{no\\_screen} + L$$\nThis equation demonstrates that the observed post-diagnosis survival time is artificially inflated by an amount exactly equal to the lead time $L$. This phenomenon is known as lead-time bias. The patient does not live any longer (since $T$ is unchanged), but appears to survive longer after diagnosis simply because the diagnosis was made earlier.\n\nThe problem then asks for the multiplicative change in *mean* observed post-diagnosis survival that would be reported by an Uncontrolled Before-After (UBA) comparison. This corresponds to the ratio of the mean observed survival after screening to the mean observed survival before screening.\n\nThe mean observed post-diagnosis survival without screening is the expectation of $U_{no\\_screen}$:\n$$\\mathbb{E}[U_{no\\_screen}] = \\mathbb{E}[T - S]$$\nUsing the linearity of the expectation operator, we have:\n$$\\mathbb{E}[U_{no\\_screen}] = \\mathbb{E}[T] - \\mathbb{E}[S]$$\n\nThe mean observed post-diagnosis survival with screening is the expectation of $U_{screen}$:\n$$\\mathbb{E}[U_{screen}] = \\mathbb{E}[T - S + L]$$\nAgain, using the linearity of expectation:\n$$\\mathbb{E}[U_{screen}] = \\mathbb{E}[T] - \\mathbb{E}[S] + \\mathbb{E}[L]$$\nThe problem states that the lead time $L$ is a constant, so its expectation is simply $L$ itself, i.e., $\\mathbb{E}[L] = L$. Thus,\n$$\\mathbb{E}[U_{screen}] = \\mathbb{E}[T] - \\mathbb{E}[S] + L$$\n\nThe multiplicative change, which we denote by $R$, is the ratio of these two mean values:\n$$R = \\frac{\\mathbb{E}[U_{screen}]}{\\mathbb{E}[U_{no\\_screen}]} = \\frac{\\mathbb{E}[T] - \\mathbb{E}[S] + L}{\\mathbb{E}[T] - \\mathbb{E}[S]}$$\n\nFinally, we compute the numerical value of this factor for the given scenario. The provided values are:\n$\\mathbb{E}[T] = 10$ years\n$\\mathbb{E}[S] = 4$ years\n$L = 1.5$ years\n\nSubstituting these values into the derived expression for $R$:\n$$R = \\frac{10 - 4 + 1.5}{10 - 4}$$\nFirst, we evaluate the denominator, which is the mean post-diagnosis survival without screening:\n$$\\mathbb{E}[U_{no\\_screen}] = 10 - 4 = 6 \\text{ years}$$\nNext, we evaluate the numerator, which is the mean post-diagnosis survival with screening:\n$$\\mathbb{E}[U_{screen}] = 6 + 1.5 = 7.5 \\text{ years}$$\nThe multiplicative change is the ratio:\n$$R = \\frac{7.5}{6} = 1.25$$\nThe problem requires the answer to be rounded to four significant figures. The exact value $1.25$ can be expressed with four significant figures by appending trailing zeros.\n$$R = 1.250$$\nThis result indicates that the UBA comparison would incorrectly conclude that the screening program increased the mean post-diagnosis survival by a factor of $1.25$, or by $25\\%$. This entire apparent benefit is an artifact of lead-time bias, as the true survival time from biological onset ($T$) was unaffected by the program.",
            "answer": "$$\\boxed{1.250}$$"
        },
        {
            "introduction": "The decision to implement a screening program requires a careful balancing act, weighing potential life-saving benefits against inevitable harms like patient anxiety and complications from follow-up procedures. This culminating practice guides you through a comprehensive harm-benefit analysis, moving beyond single metrics to a holistic evaluation. By quantifying and comparing the expected number of deaths averted to the harms from false positives and invasive tests, you will learn to model the complex trade-offs inherent in public health decision-making .",
            "id": "4577312",
            "problem": "A health system is evaluating whether a disease with a long preclinical detectable phase and an effective early treatment meets the characteristics of a screenable disease in a cohort of $N = 1{,}000$ adults aged $55$–$74$. The screening test has sensitivity $Se = 0.92$ and specificity $Sp = 0.94$. The disease prevalence in this cohort over the next year is $p = 0.015$. All individuals with a positive screening test are offered confirmatory biopsy; the probability that a person with a positive screening test undergoes biopsy is $b = 0.85$. The probability of a major complication from biopsy is $c_{m} = 0.007$, assumed independent of disease status. For those with the disease, clinical detection (in the absence of screening) would carry a $5$-year disease-specific mortality of $m_{c} = 0.35$. Early detection through screening followed by treatment reduces disease-specific mortality by a Relative Risk Reduction (RRR) of $RRR = 0.30$ compared to clinical detection. Among those with true positive screening results who undergo biopsy, the probability of adhering to and completing effective treatment is $t = 0.90$.\n\nAssume the following:\n- Sensitivity $Se$ is the probability of a positive test given disease, and specificity $Sp$ is the probability of a negative test given no disease.\n- Each positive screening result independently leads to biopsy with probability $b$.\n- A major biopsy complication is counted as a single harm event.\n- A false positive biopsy (biopsy performed in a person without disease) is counted as a single harm event.\n- A death averted occurs when a person with disease is detected early via screening, undergoes biopsy, completes effective treatment, and experiences the absolute reduction in mortality implied by the relative risk reduction.\n\nUsing these assumptions and only the provided quantities, compute the harm-to-benefit ratio per $1{,}000$ screened, defined as the expected number of harm events divided by the expected number of deaths averted. Express the final answer as a pure number with no units. Round your answer to three significant figures.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. All necessary data and definitions are provided to compute a unique, meaningful solution. The problem is valid.\n\nThe objective is to compute the harm-to-benefit ratio for a screening program in a cohort of $N = 1,000$ individuals. The ratio is defined as the expected number of harm events divided by the expected number of deaths averted.\n\nFirst, we establish the baseline population counts.\n- Total cohort size: $N = 1,000$.\n- Disease prevalence: $p = 0.015$.\n- Number of individuals with the disease (D+): $N_D = N \\times p = 1,000 \\times 0.015 = 15$.\n- Number of individuals without the disease (D-): $N_{\\neg D} = N \\times (1-p) = 1,000 \\times (1-0.015) = 985$.\n\nThe calculation is structured into two parts: the expected benefit (denominator) and the expected harm (numerator).\n\n**1. Calculation of Expected Deaths Averted (Benefit)**\n\nA death is averted if an individual with the disease successfully navigates the screening and treatment pathway and experiences the associated reduction in mortality. This constitutes a chain of events:\n\n- The individual must have the disease: $N_D = 15$.\n- The individual must test positive. These are True Positives ($N_{TP}$). The number is determined by the test's sensitivity ($Se = 0.92$).\n$$N_{TP} = N_D \\times Se = 15 \\times 0.92 = 13.8$$\n- The individual must undergo a biopsy following the positive test. The probability of this is $b = 0.85$.\n$$N_{\\text{TP, biopsy}} = N_{TP} \\times b = 13.8 \\times 0.85 = 11.73$$\n- The individual must adhere to and complete treatment. The probability of this is $t = 0.90$.\n$$N_{\\text{treated}} = N_{\\text{TP, biopsy}} \\times t = 11.73 \\times 0.90 = 10.557$$\nThis gives the expected number of individuals who are eligible for the benefit of screening.\n\nThe benefit itself is the Absolute Risk Reduction ($ARR$) in mortality.\n- Mortality with clinical detection: $m_c = 0.35$.\n- Relative Risk Reduction from early treatment: $RRR = 0.30$.\n- The $ARR$ is the absolute difference in mortality risk:\n$$ARR = m_c \\times RRR = 0.35 \\times 0.30 = 0.105$$\nThe expected number of deaths averted, $B_{exp}$, is the product of the number of individuals successfully treated and the $ARR$ per individual.\n$$B_{exp} = N_{\\text{treated}} \\times ARR = 10.557 \\times 0.105 = 1.108485$$\n\nSymbolically, the expected benefit is:\n$$B_{exp} = (N \\cdot p \\cdot Se \\cdot b \\cdot t) \\times (m_c \\cdot RRR)$$\n\n**2. Calculation of Expected Harm Events (Harm)**\n\nHarm events are defined by two components: major biopsy complications and false positive biopsies. The problem states that each is counted as a single harm event. Based on this wording, we interpret the total number of harm events as the sum of the occurrences of these two event types.\n$$H_{exp} = E[\\text{major complications}] + E[\\text{false positive biopsies}]$$\n\n- **Harm from False Positive Biopsies:** A false positive biopsy is defined as a biopsy performed on a person without the disease. First, we find the number of false positive screening tests ($N_{FP}$) using the specificity $Sp = 0.94$.\n$$N_{FP} = N_{\\neg D} \\times (1 - Sp) = 985 \\times (1 - 0.94) = 985 \\times 0.06 = 59.1$$\nThe expected number of biopsies in these disease-free individuals is:\n$$E[\\text{false positive biopsies}] = N_{FP} \\times b = 59.1 \\times 0.85 = 50.235$$\n\n- **Harm from Major Biopsy Complications:** Complications can occur in any individual who undergoes a biopsy, regardless of their disease status. We first need the total number of biopsies.\nTotal positive tests: $N_{\\text{test+}} = N_{TP} + N_{FP} = 13.8 + 59.1 = 72.9$.\nTotal biopsies: $N_{\\text{biopsy}} = N_{\\text{test+}} \\times b = 72.9 \\times 0.85 = 61.965$.\nThe probability of a major complication from a biopsy is $c_m = 0.007$.\nThe expected number of major complications is:\n$$E[\\text{major complications}] = N_{\\text{biopsy}} \\times c_m = 61.965 \\times 0.007 = 0.433755$$\n\n- **Total Expected Harm Events:**\nThe total expected number of harm events, $H_{exp}$, is the sum of these two components.\n$$H_{exp} = 50.235 + 0.433755 = 50.668755$$\n\nSymbolically, the expected harm is:\n$$H_{exp} = [N(1-p)(1-Sp)b] + [N(p \\cdot Se + (1-p)(1-Sp))b \\cdot c_m]$$\n\n**3. Calculation of the Harm-to-Benefit Ratio**\n\nThe ratio is a dimensionless quantity calculated as:\n$$\\text{Ratio} = \\frac{H_{exp}}{B_{exp}} = \\frac{50.668755}{1.108485} \\approx 45.7143$$\n\nThe problem requires rounding the final answer to three significant figures.\n$$\\text{Ratio} \\approx 45.7$$\nThis indicates that for every death averted by the screening program, an estimated $45.7$ harm events occur.",
            "answer": "$$\\boxed{45.7}$$"
        }
    ]
}